Ignite Creation Date:
2024-05-05 @ 4:36 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00275821
Status:
COMPLETED
Last Update Posted:
2011-03-16
First Post:
2006-01-11
Brief Title:
Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization CNV Secondary to Age-related Macular Degeneration AMD
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Randomized Double-masked Active-controlled Multi-center Study Comparing the Efficacy and Safety of Ranibizumab Administered as Two Dosing Regimens in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration
Status:
COMPLETED
Status Verified Date:
2011-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
EXCITE
Brief Summary:
The study will test if the efficacy and safety of an alternative dosing regimen is as effective as monthly injections
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None